239 withdrawn. 239 Phase 2, 32 Phase 1, 23 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 239 | Withdrawn 239 |
| Phase 1 | 32 | Withdrawn 32 |
| Phase 3 | 23 | Withdrawn 23 |
Follow Mental Disorders: new trials by email Literature Review of Mental Disorders trials Research Report on Mental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2050-01-01 | 2021-04-19 | |
| Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder Psilocybin - Opioid Use Disorder | Phase 2 | Withdrawn | Johns Hopkins University | 2027-04-01 | 2026-02-23 | |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation Dexmedetomidine (IV) 0.5 mcg/kg, Placebo - Abortion, Stillbirth | Phase 2 / Phase 3 | Withdrawn | Stanford University | 2026-07-01 | 2026-07-17 | |
| Post-Operative Steroids After Sleep Surgery 8mg dexamethasone - Obstructive Sleep Apnea | Phase 2 | Withdrawn | Medical University of South Carolina | 2026-07-01 | 2026-10-06 | |
| Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual Buprenorphine SL, Telehealth, In-person treatment as usual - Opioid Use Disorder | Phase 2 | Withdrawn | New York State Psychiatric Institute | 2026-06-01 | 2026-09-08 | |
| Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals Lidocaine 2% Injectable Solution, Placebo - Anxiety | Phase 2 | Withdrawn | University of Calgary | 2026-05-06 | 2026-05-01 | |
| Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies fMRI Neurofeedback, Accelerated theta burst stimulation, Psilocybin assisted therapy - Suicidal Ideation | Phase 2 | Withdrawn | University of New Mexico | 2026-05-01 | 2026-03-20 | |
| Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder Intermittent theta burst repetitive transcranial magnetic stimulation (iTBS) - Major Depressive Disorder | Phase 2 | Withdrawn | National Institute of Mental Health (NIMH) | 2026-04-25 | 2026-04-28 | |
| N2O for Acute Suicidality and Depression in the ED Nitrous oxide gas for inhalation, Placebo - Suicidal Ideation, Major Depressive Disorder | Phase 2 | Withdrawn | University of Chicago | 2026-02-27 | 2026-03-04 | |
| A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders Midomafetamine, Non-directive therapy, Therapy - Anorexia Nervosa Restricting Type, Binge-Eating Disorder | Phase 2 | Withdrawn | Resilient Pharmaceuticals | 2026-02-01 | 2024-10-31 | |
| The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series interpersonal psychotherapy (IPT), Ketamine - Postpartum Depression | Phase 2 / Phase 3 | Withdrawn | Washington University School of Medicine | 2025-10-15 | 2025-10-29 | |
| Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room Intranasal Dexmedetomidine (4 mcg/kg), Intranasal Fentanyl (2 mcg/kg), Intranasal Midazolam (5 mg/kg) - Acute Stress Disorder, Anxiety | Phase 2 | Withdrawn | Nationwide Children's Hospital | 2025-09-01 | 2025-09-10 | |
| Trifecta Research Study Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment - PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction | Phase 2 | Withdrawn | Johns Hopkins University | 2025-09-01 | 2025-08-22 | |
| Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder ED-Initiated treatment with buprenorphine / naloxone - Opioid-use Disorder | Phase 2 | Withdrawn | University of California, Davis | 2025-07-30 | 2024-11-12 | |
| MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents MDMA, Psychotherapy - PTSD, Post Traumatic Stress Disorder, Adolescents | Phase 2 | Withdrawn | University of California, Los Angeles | 2025-07-01 | 2025-04-10 | |
| Investigating the Protective Impact of LY-2940094 on Stress-induced Depression- and Anxiety-related Phenotypes in Humans Nociceptin Receptor Antagonist (LY-2940094), DS8R Biphasic Constant Current Stimulator - Depression - Major Depressive Disorder, Anxiety | Phase 2 | Withdrawn | Mclean Hospital | 2025-06-01 | 2025-09-25 | |
| SNIFF - 3-Week Aptar CPS Device Insulin (Humulin® R U-100), Placebo, Aptar Pharma CPS Intranasal Delivery Device - Mild Cognitive Impairment, Cognitive Impairment | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2025-05-01 | 2025-07-28 | |
| Repeated Neurocognitive Measurements in Depressed Patients Intravenous Ketamine - Depression, Unipolar | Phase 1 / Phase 2 | Withdrawn | Jay Fournier | 2025-05-01 | 2026-02-25 | |
| Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen - Migraine | Phase 2 | Withdrawn | Allodynic Therapeutics, Inc | 2025-01-31 | 2025-12-08 |
Showing 20 of 239. Sign in to see all of them.
Opioid-Related Disorders (23) · Stress Disorders, Post-Traumatic (22) · Depression (21) · Alzheimer Disease (20) · Schizophrenia (20) · Alcoholism (18) · Anxiety Disorders (16) · Depressive Disorder, Major (16) · Marijuana Abuse (15) · Substance-Related Disorders (14) · Autism Spectrum Disorder (11) · Autistic Disorder (11) · Bipolar Disorder (11) · Cognitive Dysfunction (11) · Tobacco Use Disorder (9)
Chemically-Induced Disorders (73) · Substance-Related Disorders (59) · Nervous System Diseases (54) · Behavior (40) · Neurocognitive Disorders (37) · Central Nervous System Diseases (34) · Pathological Conditions, Signs and Symptoms (33) · Brain Diseases (32) · Mood Disorders (30) · Neurodegenerative Diseases (26) · Signs and Symptoms (25) · Behavioral Symptoms (24) · Neurodevelopmental Disorders (24) · Narcotic-Related Disorders (23)
nabiximols (8) · Ketamine (7) · Psilocybin (7) · Cannabidiol (6) · Dexmedetomidine (6) · Sugars (6) · Valproic Acid (5) · Cycloserine (4) · N-Methyl-3,4-methylenedioxyamphetamine (4) · Naltrexone (4) · Sodium Chloride (4) · Therapeutics (4) · Transcranial Magnetic Stimulation (4) · Varenicline (4) · Buprenorphine (3)
Yale University (9) · University of Colorado, Denver (7) · National Institute of Mental Health (NIMH) (6) · Johns Hopkins University (5) · Massachusetts General Hospital (5) · Pfizer (5) · University of California, Los Angeles (5) · Boston Children's Hospital (4) · New York State Psychiatric Institute (4) · Sadat City University (4) · Washington University School of Medicine (4) · Ageless Regenerative Institute (3) · Centre for Addiction and Mental Health (3) · Duke University (3) · Ewha Womans University (3)
United States (129) · Canada (10) · Israel (5) · Australia (4) · China (4) · Egypt (4) · South Korea (4) · France (3) · Germany (2) · Brazil (1) · Denmark (1) · India (1) · Iran (1) · Jamaica (1) · Japan (1)
Leslie Amass, Ph.D. (6) · Marc I Rosen, M.D. (5) · Sharon McQuillan, MD (3) · Albert Arias, MD (2) · Anna Rose Childress, PhD (2) · Baorong Zhang, MD (2) · Inkyoon Lyoo, MD, PhD, MMS (2) · John R Knight, MD (2) · Peter Nagele, MD, MSc (2) · Robert Freedman, MD (2) · Sandeep Nayak, MD (2) · Adele Lafrance, PhD (1)
PMID 12648025, PMID 15094417, PMID 16317825, PMID 17063973, PMID 17566383, PMID 17916224, PMID 18728826, PMID 19587829, PMID 19883531, PMID 19896326, PMID 20076976, PMID 21049267, PMID 22076835, PMID 22464727, PMID 23141881, PMID 25974235, PMID 26144593, PMID 26257143, PMID 26883879, PMID 27403414, PMID 29486960, PMID 31527291, PMID 32178232, PMID 32425802, PMID 33605440, PMID 34173005, PMID 37243560, PMID 40046866
R01DA011160 (6), K20DA000191 (5), 2019 (2), 1UF1AG046143 (1), 2017 (1), I01CX002357 (1), I21RX003323 (1), K01AA026005 (1), K01DA025073 (1), K08MH094441 (1), K23DA014291 (1), K23MH125315 (1), P50DA018165 (1), P50DA027840 (1), P50MH119467 (1)